On July 31, Stryker fell 6.54% in pre-market trading, trading at $325.11/share, with turnover of $158,300. The decline followed the company's Q2 earnings release after market close on July 30, which triggered heavy selling pressure.

While overall Q2 results exceeded expectations — adjusted EPS of $3.69 beat the $3.49 consensus by 5.73%, representing a 17.89% year-over-year increase, and net sales of $6.589 billion slightly topped the $6.579 billion estimate — the company's largest revenue segment, MedSurg and Neurotechnology, posted sales of $3.6 billion, falling short of the $3.72 billion analyst estimate. Additionally, Stryker narrowed its full-year adjusted EPS guidance to $14.95-$15.10 from the prior $14.90-$15.10, an extremely modest raise given the significant Q2 beat. The limited upside to guidance raised market concerns about growth sustainability in the second half. Lingering worries from a Q1 cybersecurity incident that previously caused earnings to miss estimates further weighed on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)